Dual-target, dual-payload ADCs to overcome tumor heterogeneity and resistance

“Instead of fighting tumor adaptation, we are using it to guide our design.”

Lauren Coyle, Launch Commissioning Editor, Bioconjugate Insights, speaks with Ya-Chi Chen, Chief Scientific Officer, OBI Pharma, about the design of a bispecific, dual-payload ADC, and how this strategy aims to address tumor resistance, heterogeneity, and payload limitations in difficult-to-treat cancers.

Please enter your email to access content Read now